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Background: CKD is a recognized complication of metabolic syndrome (MetS) and may contribute to additional CV risk. This sub-analysis of the 
TNT study investigated the effect of intensive lipid lowering with atorvastatin (ATV) 80 mg on the incidence of major CV events (MCVE)(CHD death, 
nonfatal MI, resuscitated cardiac arrest, or stroke) compared with ATV 10 mg in stable coronary patients with MetS and CKD.
Methods: Following 8 weeks’ open-label therapy with ATV 10 mg, 10,001 CHD patients were randomized to double-blind therapy with ATV 10 mg or 
80 mg for a follow-up of 4.9 years. CKD was defined as a glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2.
Results: Prevalence of CKD was significantly higher in subjects with MetS (35.2%) vs those without MetS (28.2%) in the 9500 patients who 
had complete renal data (P<0.0001). Patients with both MetS and CKD were at greater risk of MCVE than those with either condition alone and 
significantly greater risk than those with neither condition (Table). Compared with ATV 10mg, ATV 80mg reduced event rates in all 4 CKD and MetS 
cross-classification groups. Among those coronary patients with MetS and CKD, the relative risk of MCVE was significantly reduced by 35% in the 80 
mg group vs the 10 mg group (HR=0.65, 95% CI 0.49-0.86; P=0.003).
Conclusion: CKD is a frequent and important co-morbidity that contributes to additional CV risk in MetS patients with CHD. High-dose ATV 80 mg 
significantly reduced the incidence of MCVE, compared with ATV 10 mg in coronary patients with MetS and CKD.
N
MCVE
n (%)
HR
(95% CI)
P
No CKD/No MetS 3023 178 (5.9) 1.00 -
CKD alone 1190 90 (7.6) 1.31 (1.01, 1.68) 0.0388
MetS alone 3428 286 (8.3) 1.44 (1.20, 1.74) 0.0001
CKD + MetS 1859 203 (10.9) 1.92 (1.57, 2.35) <0.0001
